van der Voort EI - Search Results

1

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. Schoenberger SP, et al. Among authors: van der voort ei. Nature. 1998 Jun 4;393(6684):480-3. doi: 10.1038/31002. Nature. 1998. PMID: 9624005

2

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.

van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE. van Mierlo GJ, et al. Among authors: van der voort ei. Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6. doi: 10.1073/pnas.082107699. Epub 2002 Apr 2. Proc Natl Acad Sci U S A. 2002. PMID: 11929985 Free PMC article.

3

Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.

Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Toes RE, et al. Cancer Res. 1996 Aug 15;56(16):3782-7. Cancer Res. 1996. PMID: 8706024

4

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ. Vierboom MP, et al. Among authors: van den broek l, van hall t, van der voort ei. J Exp Med. 1997 Aug 29;186(5):695-704. doi: 10.1084/jem.186.5.695. J Exp Med. 1997. PMID: 9271585 Free PMC article.

5

Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.

Toes RE, van der Voort EI, Schoenberger SP, Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R, Melief CJ. Toes RE, et al. Among authors: van der voort ei, van bloois l. J Immunol. 1998 May 1;160(9):4449-56. J Immunol. 1998. PMID: 9574550

6

Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells.

Schoenberger SP, van der Voort EI, Krietemeijer GM, Offringa R, Melief CJ, Toes RE. Schoenberger SP, et al. Among authors: van der voort ei. J Immunol. 1998 Oct 15;161(8):3808-12. J Immunol. 1998. PMID: 9780143

7

CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity.

Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ. Toes RE, et al. Among authors: van der voort ei. Semin Immunol. 1998 Dec;10(6):443-8. doi: 10.1006/smim.1998.0147. Semin Immunol. 1998. PMID: 9826577 Review.

8

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.

Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. Diehl L, et al. Among authors: van der voort ei. Nat Med. 1999 Jul;5(7):774-9. doi: 10.1038/10495. Nat Med. 1999. PMID: 10395322

9

Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.

Schuurhuis DH, Laban S, Toes RE, Ricciardi-Castagnoli P, Kleijmeer MJ, van der Voort EI, Rea D, Offringa R, Geuze HJ, Melief CJ, Ossendorp F. Schuurhuis DH, et al. Among authors: van der voort ei. J Exp Med. 2000 Jul 3;192(1):145-50. doi: 10.1084/jem.192.1.145. J Exp Med. 2000. PMID: 10880536 Free PMC article.

10

The role of CD40 in peripheral T cell tolerance and immunity.

Diehl L, Den Boer AT, van der Voort EI, Melief CJ, Offringa R, Toes RE. Diehl L, et al. Among authors: van der voort ei. J Mol Med (Berl). 2000;78(7):363-71. doi: 10.1007/s001090000126. J Mol Med (Berl). 2000. PMID: 11043379 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

46 results

Search Page